(Reuters) -Eli Lilly and Co on Wednesday appointed a new chief for its diabetes and obesity unit in a string of leadership changes ahead of a key regulatory decision on the use of its potential blockbuster drug Mounjaro as a weight-loss treatment.
Slideshow ( 2 images )Mounjaro, chemically known as tirzepatide, is already being prescribed by doctors off-label as an obesity treatment.
In his new role, Jonsson will oversee Lilly’s launched products and late-stage development of diabetes and obesity treatments, including tirzepatide and other candidates such as its next-generation obesity drug retatrutide and obesity pill orforglipron.
Mason, who has also spent more than three decades with Lilly, oversaw the late-stage development and the launch of Mounjaro.
The diabetes drug, which clocked in sales of $979.7 million in the latest quarter, belongs to a class of drugs known as GLP-1s that stimulate insulin production.
Persons:
Eli Lilly, Patrik Jonsson, Lilly USA, Mike Mason, Jonsson, Lilly’s, Mason, Lilly, Daniel Skovronsky
Organizations:
Reuters
Locations:
Sweden, Scandinavia, Italy, Japan, Jonsson